Leading Medical Centers Join Growing Number of Locations Offering IsoRay Medical, Inc.'s Prostate Cancer Treatment Proxcelan(TM) Brachytherapy Seeds (Cesium-131)

RICHLAND, Wash.--(BUSINESS WIRE)--University of Pittsburgh Medical Center (UPMC), and Arizona Oncology Services (AOS) are two of the latest leading medical facilities offering prostate cancer patients the breakthrough Proxcelan™ brachytherapy seeds (Cesium-131). Proxcelan is a proprietary product of IsoRay Medical™ - a wholly owned subsidiary of a public company, IsoRay, Inc. (“IsoRay”) (AMEX:ISR), based in Richland, WA. Proxcelan has Food & Drug Administration 510(k) clearance for treating prostate cancer and other malignancies.